ExpreS2ion Biotech Holding AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXPRS2.ST research report →
Companywww.expres2ionbio.com
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine.
- CEO
- Bent U. Frandsen
- IPO
- 2016
- Employees
- 20
- HQ
- Horsholm, DK
Price Chart
Valuation
- Market Cap
- $7.39M
- P/E
- -0.25
- P/S
- 2.02
- P/B
- 0.26
- EV/EBITDA
- 0.83
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -465.76%
- Op Margin
- -1348.46%
- Net Margin
- -1041.43%
- ROE
- -93.63%
- ROIC
- -113.81%
Growth & Income
- Revenue
- $3.66M · 21.37%
- Net Income
- $-38,085,000 · -5.68%
- EPS
- $-13.39 · 37.17%
- Op Income
- $-52,820,000
- FCF YoY
- -17.55%
Performance & Tape
- 52W High
- $34.20
- 52W Low
- $1.65
- 50D MA
- $3.40
- 200D MA
- $13.73
- Beta
- 2.20
- Avg Volume
- 50.34K
Get TickerSpark's AI analysis on EXPRS2.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EXPRS2.ST Coverage
We haven't published any research on EXPRS2.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EXPRS2.ST Report →